Results 161 to 170 of about 4,521 (193)

P115 Long-term efficacy of filgotinib monotherapy and combination therapy: interim results from a post hoc analysis of the FINCH 4 study

Rheumatology
Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA). This post hoc, interim analysis of FINCH 4 (NCT03025308) characterizes the long-term efficacy of FIL administered as ...
M. Buch, P. Verschueren, R. Caporali, Thomas Huizinga, Edmund Omoruyi, Dick de Vries, J. Ritsema, Francesco De Leonardis, D. Aletaha   +8 more
semanticscholar   +1 more source

OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years

Rheumatology
Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA) approved at doses of 100 mg (FIL100) and 200 mg (FIL200).
Kevin L Winthrop, D. Aletaha, R. Caporali, Yoshiya Tanaka, Tsutomu Takeuchi, M. Buch, V. Modgill, Edmund Omoruyi, Dick de Vries, K. Van Beneden, J. Gottenberg, Gerd R. Burmester   +11 more
semanticscholar   +1 more source

P0786 The short-term efficacy of Filgotinib on antibiotic-dependent/resistant pouchitis in patients with ulcerative colitis

Journal of Crohn's & Colitis
In surgeries for ulcerative colitis, total colectomy and ileal pouch-anal anastomosis are the standard procedures, but one of the postoperative issues is developing pouchitis.
M. Uchino, H. Ikeuchi, Y. Horio, R. Kuwahara, K. Kusunoki, K. Nagano, Y. Tomoo, K. Nomura   +7 more
semanticscholar   +1 more source

P1145 Comparison of Clinical Relapse between Tofacitinib and Filgotinib as Maintenance Therapy in Ulcerative Colitis Patients in Clinical Remission: A Retrospective Propensity Score-Matched Cohort Study

Journal of Crohn's & Colitis
Strategies to reduce relapse after induction therapy using JAK inhibitor are controversial in patients with ulcerative colitis (UC). In this study, we aimed to compare relapse rate between tofacitinib (TOF) treatment and filgotinib (FIL) treatment ...
S. Yagi, H. Fukui, M. Ikenouchi, T. Shiraishi, M. Wakita, Y. Takagi, T. Sato, M. Kawai, K. Kamikozuru, Y. Yokoyama, T. Takagawa, S. Shinzaki   +11 more
semanticscholar   +1 more source

Efficacy and safety of filgotinib in the treatment of ulcerative colitis with a focus on rapid and sustained efficacy: a narrative review.

Intestinal Research
The rising incidence of ulcerative colitis (UC) globally highlights the necessity for treatment strategies that extend beyond symptom control to include inducing and maintaining remission, achieving biochemical and endoscopic remission, and restoring ...
T. Hisamatsu, T. Kaise, Chisa Nagakura, M. Kamiya, Shu-Chen Wei   +4 more
semanticscholar   +1 more source

Filgotinib in ulcerative colitis in clinical practice: real-world data published in 2025

Gastroenterology & hepatology
Filgotinib is a preferential JAK-1 inhibitor, which was introduced in clinical practice in ulcerative colitis patients in 2022. In that year, many real-world clinical data have been published, documenting that filgotinib therapy is associated with high ...
Milan Lukas, Martin Lukáš
semanticscholar   +1 more source

P1144 Effect of baseline disease severity on achieving efficacy endpoints in patients with Ulcerative Colitis treated with filgotinib

Journal of Crohn's & Colitis
Data from the real-world GALOCEAN study showed that ~70% of patients have moderately active Ulcerative Colitis (UC).1 A post hoc analysis of the SELECTION study (NCT02914522) found that patients with moderately active UC were more likely to have ...
M. Allez, J. Burisch, B. Verstockt, A. Dignass, G. Fiorino, Y. Zabana, M. Saruta, W. Sawyer, C. Rudolph, V. Vyncke, P. Irving   +10 more
semanticscholar   +1 more source

P0790 Effectiveness of Tofacitinib and Filgotinib as An Induction Therapy for Patients with Moderate-to-Severe Ulcerative Colitis: Real-World Comparison in Propensity Score-Matching Analysis

Journal of Crohn's & Colitis
There are few data comparing the efficacy and safety of each Janus kinase (JAK) inhibitors in ulcerative colitis (UC) patients. We aimed to compare the real-world effectiveness and safety of tofacitinib (TOF) and filgotinib (FIL) which are JAK ...
S. Yagi, H. Fukui, M. Ikenouchi, T. Shiraishi, M. Wakita, Y. Takagi, T. Sato, M. Kawai, K. Kamikozuru, Y. Yokoyama, T. Takagawa, T. Tomita, S. Shinzaki   +12 more
semanticscholar   +1 more source

P1054 Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study

Journal of Crohn's & Colitis
Filgotinib (FILGO), a selective anti-JAK1, has obtained refundability from the Italian National Health System in February 2023 for its use in patients with Ulcerative Colitis (UC) refractory to other therapies, including anti-TNF-α, anti-integrins ...
G. Mocci MD FRCP, F. Costa, L. Ceccarelli, E. Savarino, C. Mucherino, M. Marzo, F. Scaldaferri, D. Napolitano, D. Pugliese, A. G. Gravina, R. Pellegrino, R. Spagnuolo, A. Cuomo, G. Maconi, L. Bertani, G. Bodini, G. Orrù, S. Piergallini, A. Scarcelli, P. Capone, F. Cortellini, S. Rodino, G. Vespere, F. Gaiani, C. Pagnini, G. Graziani, L. Allegretta, A. Ferronato, D. Ribaldone, G. Aragona, G. Forti, M. Di Fonzo, F. Iacopini, R. Pica, M. F. Onidi, P. Usai Satta, W. Elisei, M. Picchio, A. Papa, A. Tursi   +39 more
semanticscholar   +1 more source

P0681 Filgotinib for active Ulcerative Colitis in clinical practice - Effective treatment at week 8 is associated with higher clinical remission and persistence rates at Week 52 -

Journal of Crohn's & Colitis
There are few reports on therapeutic outcomes one year after starting filgotinib (FIL), a novel JAK inhibitor for ulcerative colitis (UC) in clinical practice. We studied the therapeutic outcomes and safety of FIL at 52 weeks after its initiation.
A. Yamada, K. Yokoyama, Y. Harada, T. Ito, T. Horii, J. Kanazawa, H. Ikehara, C. Kusano   +7 more
semanticscholar   +1 more source